Non-protein bound iron (NPBI) is able to catalyse oxidative reactions, causing damage to vital structures. Adverse effects induced by cisplatin seem, in part, to be mediated by free radicals. In the present study, we have measured plasma NPBI, various other iron parameters and antioxidants in 28 cancer patients undergoing cisplatin-based chemotherapy at various time points before and during chemotherapy. No NPBI was present prior to therapy, but within 1-4 days following the first administration of chemotherapy, mean NPBI rose significantly to 10.6 + − 6.6 µmol/l (range, 0.6-21.3 µmol/l) in 18 (64.3 %) of the 28 patients measured. The rise in NPBI was accompanied by a significant rise in total plasma iron and ferritin and a marked decrease in the latent iron-binding capacity. Concomitantly, plasma vitamins C and E decreased significantly, indicating consumption of antioxidants. Similar observations were also made during the fourth chemotherapy cycle. The increase in NPBI preceded and correlated significantly with chemotherapy toxicity, such as a decrease in leucocyte count and haemoglobin, with a transient rise in various liver enzymes and with known cisplatin-related toxicity, i.e. the loss of renal and hearing function. In conclusion, cisplatin chemotherapy induces oxidative damage which rapidly leads to release of iron from intracellular proteins and the appearance of NPBI. Bone marrow, red blood cells, liver and kidney seem to be a likely source of NPBI. The observed high levels of NPBI may be a major causative determinant in chemotherapy-induced toxicity.
INTRODUCTION
Non-protein bound iron (NPBI) in the reduced form is a powerful promoter of free radical damage and highly toxic to biological systems, resulting in oxidative damage to lipids, proteins and DNA [1] . Iron toxicity is prevented because iron is tightly bound to circulating and intracellular proteins. Most of the body's iron is found intracellularly bound to ferritin, capable of storing up to 4500 iron (FeIII) atoms/ferritin molecule, haemosiderin or haem, and extracellularly attached to high-tissues for normal metabolic activities [2,2a] . Its strong reducing potential makes vitamin C an efficient free radical scavenger; however, because it can also reduce and then activate iron, it can act as a double-edge sword. Oxidation of vitamin C produces dehydroascorbic acid which, however, can be recycled back to reduced vitamin C (ascorbic acid) via dehydroascorbate reductase. Binding of iron to transport proteins can only occur when the iron is in the oxidized (ferric, Fe 3+ ) form, whereas reduced (ferrous, Fe 2+ ) iron is a highly reactive ion which catalyses the formation of the hydroxyl radical from H 2 O 2 [2, 3] .
Animal and clinical studies suggest that NPBI-induced oxidative damage plays an important role in sepsisand ischaemia/reperfusion-induced acute renal and heart failure [4] [5] [6] and side-effects of cytostatic agents, such as cisplatin, doxorubicin and bleomycin [7] . In vitro and animal studies have indicated that cisplatin-induced renal tubular damage and emesis were mediated by the formation of plasma NPBI [8] [9] [10] , whereas prevention of NPBI by chelation with desferrioxamine ameliorated these toxic effects [8, 9] . Similar clinical interventions may decrease anthracyclin-induced cardiotoxicity [7, 11] .
We [12] have demonstrated previously that, in patients treated with cisplatin chemotherapy, plasma levels of various antioxidants decrease profoundly. To investigate whether NPBI could be implicated in toxicities induced by chemotherapy, in the present study we measured NPBI in plasma of cancer patients treated with cisplatinbased chemotherapy.
METHODS

Patients
Twenty-eight consecutive patients [25 men and three women, with a mean age of 45 + − 15 years (range, 16-68 years)] treated in the Department of Clinical Oncology at the Leiden University Medical Center were studied after they had given informed consent. Patients received cycles of intravenously (i.v.) administered combination chemotherapy, each cycle consisting of 3-5 days of cytostatic drug infusions, followed by a rest period. Cycles were repeated every 21 days. None of the patients had been treated before with cytotoxic agents. All patients were in good clinical condition (World Health Organization performance score of 0 or 1).
Eight (28.6 %) patients with disseminated germ-cell cancer (mean + − S.E.M. age, 32 + − 9 years) were treated with the bleomycin/etoposide/cisplatin (BEP) regimen, consisting of 30 2 cisplatin on day 1 alone. All patients were admitted to hospital 1 day prior to each cisplatin infusion and remained until 1 day after completion of the cytostatic drug infusion. Patients received 3-4 litres/day of 0.9 % NaCl and 5 % (w/v) glucose i.v. to reduce cisplatin-mediated nephrotoxicity. Patients received granisetron with or without dexamethasone in the first 3-7 days of each cycle as antiemetic medication.
The 28 consecutive patients participated in a larger randomized, placebo-controlled, double-blind trial, in which patients received either supplementation with vitamins C and E (α-tocopherol) and selenium or received placebo (N. I. Weijl, T. J. Elsendoorn, E. G. W. M. Lentjes, G. D. Hopman, A. Wipkink-Bakker, A. H. Zwinderman, F. J. Cleton and S. Osanto, unpublished work). Of these 28 patients, 10 received oral supplementation with beverages containing vitamins C and E (α-tocopherol) and selenium at daily doses of 2000 mg, 800 international units and 200 µg respectively, starting 7 days before and during chemotherapy in an attempt to augment antioxidant defences. The other 18 patients received placebo beverages twice daily. Two patients used granulocyte colony-stimulating factor (G-CSF) during the whole treatment period as part of a treatment protocol, two others received G-CSF after the third chemotherapy cycle, because of profound granulocytopenia during previous chemotherapy courses. Patients having a decreasing blood haemoglobin concentration to less than approx. 5.5 mmol/l generally received transfusion of packed red blood cells in order to maintain their blood haemoglobin concentration above this level. Fourteen patients received a total of 65 units of packed red blood cell units, mostly during, and a short time after, surgery for osteosarcoma.
Most of the 28 patients had evaluatable antitumour responses and responded favourably to chemotherapy, whereas only four patients had progressive disease despite chemotherapy.
Blood sampling
Blood specimens were drawn at the following times: (i) on admission to hospital; (ii) 1 day prior to initiation of the first, second and fourth chemotherapy course; (iii) within 24 h after the cessation of the first and fourth chemotherapy infusions on the last day of these hospital admissions (usually on days 2 to 5, depending on the chemotherapy scheme); and (iv) after the first and fourth chemotherapy course at the Outpatient Department (usually between days 8-15). All blood specimens were always drawn in the morning before the start of the chemotherapy administration. Blood samples from germcell cancer patients, who also received bleomycin as part of their BEP chemotherapy regimen on an outpatient basis, namely once a week in week 2 and 3, were drawn just before the outpatient administration of bleomycin and, thus, 1 week after the previous administration of bleomycin.
For various reasons, e.g. progression of disease during therapy, fewer patients were monitored during cycles 2, 3 and 4. Heparinized blood samples were collected and plasma was prepared by immediate centrifugation for 10 min at 500 g at 4
• C. For the determination of vitamin C, an aliquot was mixed with the same volume of 10 % (w/v) metaphosphoric acid solution and 2 mM deferoxamine. All plasma specimens were stored at − 70
• C under argon until analysis for NPBI and antioxidants within 8 weeks of collection.
Analytical methods
NPBI and other iron status parameters were simultaneously measured before the start of the first, second and fourth chemotherapy cycle, during the first and fourth cycle within 24 h after cessation of the last infusion of cytostatic drugs and at nadir days (usually between days 8-15 after the start of each chemotherapy cycle). Plasma NPBI was assessed utilizing the bleomycin assay [13] , one of the most frequently used assays in the literature [14] [15] [16] [17] [18] [19] [20] . Bleomycin-detectable iron represents iron ions bound to low-molecular-mass chelating agents, such as citrate, or loosely bound to certain proteins. Bleomycin binds non-protein-bound iron and the resulting bleomycin-iron complex can be quantified by its ability to induce oxidative DNA damage. This oxidative DNA damage correlates directly with the initial free (catalytic) iron activity. Briefly, plasma was incubated for 2 h at 37
• C with calf thymus DNA (Sigma, Poole Dorset, U.K.), bleomycin sulphate (Sigma), MgCl 2 and ascorbic acid solution [13] . Ascorbic acid solution was freshly prepared by dissolving ascorbic acid (Sigma) in water and shaking with Chelex-100 resin (Bio-Rad Laboratories, Hemel Hempstead, Herts., U.K.). The degradation of DNA by bleomycin in the presence of NPBI leads to the formation of a product that reacts with thiobarbituric acid to produce a chromogen.
Measurement of the absorbance at 532 nm was, therefore, used to quantify the amount of NPBI present. FeCl 3 (Sigma) was used as a calibration standard. Pyrogen-free water was used throughout, and reagents were pretreated with Chelex resin to remove contaminating iron.
Plasma C-reactive protein (CRP), transferrin, total iron and latent iron-binding capacity (LIBC) were measured on an automated clinical chemistry analyser (Hitachi 911; Roche Diagnostics, Mannheim, Germany). CRP and transferrin were measured with an immunoturbidimetric assay. The method for plasma iron is based on the ferrozine method without deproteinization. LIBC was determined by saturating transferrin at an alkaline pH with a known, but excess, amount of iron. The excess amount was quantified with the ferrozine method and subtracted from the total amount of iron added. Plasma ferritin was measured with the microparticle enzyme immunoassay on an Imx (Abbott Laboratories, Abbott, IL, U.S.A.).
Total, reduced and oxidized vitamin C [21] , total vitamin E [22] and malondialdehyde (MDA), a product of lipid peroxidation [23] , were measured by HPLC. Plasma concentrations of MDA were used as markers of oxidative stress. Liver function was assessed by measurement of plasma total bilirubin and alanine aminotransferase (ALAT) in combination with aspartate aminotransferase (ASAT), γ -glutamyltranspeptidase (GGT), alkaline phosphatase and lactate dehydrogenase. These parameters, plasma creatinine and magnesium were determined on a Synchron CX4CE clinical chemical analyser (Beckman Instruments Inc., Brea, CA, U.S.A.).
Renal function
Creatinine clearance was estimated using the formula of Cockroft and Gault [24] : glomerular filtration rate (ml/min) = 1.2 × {[140 − age (years)] × body weight (kg)}/plasma creatinine (µmol/l). In females, the result should be multiplied further by 0.85. Plasma magnesium was measured, as a decrease may result from renal tubular damage and renal tubular loss of magnesium, a known side effect of cisplatin.
Hearing function
Prior to chemotherapy and just before each subsequent chemotherapy cycle, an audiological examination was performed to measure cisplatin-mediated toxicity that usually first occurs in the high-frequency range, as described previously [25] . Air and bone conduction thresholds were obtained separately for each ear at 1.0, 2.0, 4.0 and 8.0 kHz, at 5-dB increments. If the threshold of bone conduction was < 10 dB than that of air conduction, bone conduction thresholds are reported. The results are expressed in means of conduction thresholds of both ears at the various frequencies.
Statistical analysis
Student's paired t test was used to compare the values of parameters of individual patients during one particular cycle and the values on day 1 of two distinctive cycles. Bivariate Pearson's correlation coefficients and independent samples t test were used in order to investigate the relationships between NPBI and parameters indicating the chemotherapy-induced toxicity or the possible sources of NPBI. Differences between groups and correlation coefficients were considered significant if P < 0.05.
In order to investigate the effects of the chemotherapy regimens and antioxidant supplementation on the plasma iron parameters in this heterogeneous population of cancer patients, subgroup analyses were performed using the independent samples t test. Two subgroup analyses were performed. One subgroup analysis was made to separate patients into more homogeneous groups based on chemotherapy regimen and tumour type. The three subgroups consisted of eight germ-cell cancer patients treated with the BEP regimen, nine sarcoma patients (osteosarcoma or malignant fibrous histiocytoma) treated with the CD regimen and 11 patients treated with other cisplatin-based chemotherapy regimens. Each subgroup was compared with the other subgroups as well as with the two other subgroups combined into one larger group of patients.
A second subgroup analysis was performed in the group of 10 patients who received antioxidant supplementation and the group of 18 patients receiving placebo.
Patients receiving G-CSF were excluded for statistical analysis concerning the white blood cell counts after initiation of G-CSF administration. Patients receiving red blood cell transfusion were excluded for statistical analysis concerning changes of haemoglobin concentration during one cycle after administration of the blood transfusion.
RESULTS
NPBI and other iron-related parameters
NPBI was not detected in the plasma of any of the 28 patients before the start of the first cycle (Table 1) or 2 months after completion of all of the chemotherapy cycles. However, the first chemotherapy cycle resulted in a considerable level of detectable NPBI in 18 of the 28 patients (64.3 %) studied, with a mean peak plasma NPBI of 10.6 + − 6.6 µmol/l (range, 0.6-21.3 µmol/l) in these 18 patients. Plasma NPBI was found in patients from all chemotherapy treatment groups. As NPBI was measured within 24 h after cessation of the last infusion of cytostatic drugs, it was already found to rise markedly on the second day in those patients who received a 1-day chemotherapy regimen. With the exception of one patient with a low level of NBPI (0.3 µmol/l), no NPBI was found at the start of the second cycle in the other 17 patients. During the fourth chemotherapy cycle, 17 of the 19 patients (89.5 %) had detectable plasma NPBI, with a mean value of 10.4 + − 5.7 µmol/l (range, 0.2-21 µmol/l). The mean peak plasma NPBI concentration in germ-cell cancer patients treated with the BEP chemotherapy regimen was significantly higher than the mean peak plasma NPBI level in all other patients during the first chemotherapy cycle (11.7 + − 9.2 µmol/l and 4.8 + − 5.6 µmol/l respectively; P = 0.023; Figure 1 ). During the fourth chemotherapy cycle, mean peak plasma NPBI concentrations did not differ significantly between the three treatment-based subgroups of patients (results not shown). Furthermore, mean peak NPBI levels during the first and fourth chemotherapy cycle did not differ significantly in patients receiving antioxidant supplementation compared with patients receiving placebo ( Table 1) .
Plasma iron concentrations increased from a mean of 10.7 + − 6.4 µmol/l (range, 2-23 µmol/l) before the start of treatment to a peak level of 39.6 + − 10.0 µmol/l (range, 14-55 µmol/l) during the first treatment cycle (Student's t test, P < 0.001; Table 1 ). Concomitantly, LIBC decreased during the first cycle from a mean LIBC of 49.7 + − 10.8 µmol/l (range, 36-79 µmol/l) before the start of treatment to 10.2 + − 9.2 µmol/l (range 2-39 µmol/l) during the first cycle (P < 0.001; Table 1 ). Similar changes in plasma iron levels and LIBC occurred during the fourth cycle: plasma iron levels increased from a mean of 14.0 + − 4.8 µmol/l before the start of the fourth cycle to a peak level of 41.6 + − 10.3 µmol/l during the same cycle (P < 0.001), and LIBC decreased from a mean LIBC of 38.9 + − 10.0 µmol/l before the start of the fourth cycle to a mean minimum concentration of 4.1 + − 1.7 µmol/l during the fourth cycle (P < 0.001). NPBI was only found in plasma of patients with a decrease in LIBC to less than 13 µmol/l. Of interest, plasma transferrin decreased significantly during the first and fourth cycle, whereas plasma ferritin levels increased progressively during subsequent cycles (Table 1) .
Like ferritin, plasma CRP increased significantly, but was less pronounced, during the first cycle and, thereafter, returned to baseline levels (results not shown). Levels of plasma iron and CRP at the start of the chemotherapy were not different from the levels prior to the second and fourth chemotherapy cycle. However, plasma ferritin levels rose steadily before the start of the first cycle from 161.6 + − 176.3 µmol/l (range, 13-739 µmol/l) to 485.7 + − 384.4 µmol/l (range, 18-1504 µmol/l) before the start of the fourth cycle. Also levels of LIBC and transferrin decreased significantly between the start of the first and second cycles, but not between the start of the second and the fourth cycles (Table 1) . Subgroup analyses of chemotherapy treatment subgroups and supplementation versus placebo subgroup did not show significant differences with respect to the mean plasma iron concentrations, LIBC and ferritin levels during treatment ( Figure 1 , and Table 1 ).
Plasma antioxidants and MDA
Mean vitamin C concentrations measured in all 28 patients decreased significantly from 80.0 + − 45.9 µmol/l (range, 12.2-162.8 µmol/l) prior to treatment to 38.7 + − 18.5 µmol/l (range, 8.0-74.6 µmol/l; P < 0.001) during the first chemotherapy cycle ( Table 1 ).
The decline in (total) vitamin C levels was caused mainly by a marked decrease in reduced vitamin C (Table 1) . Total vitamin E also decreased significantly (Table 1) , whereas plasma MDA increased significantly during the first cycle (results not shown). Similar changes also occurred during the fourth chemotherapy cycle (results not shown). In the 10 patients who received supplementation, plasma antioxidant levels initially increased significantly as a result of drinking of the supplementation beverages, but Peak/nadir, highest or lowest levels occurring after day 1 of the first chemotherapy cycle and before day 1 of the second chemotherapy cycle.
immediately after the start of the first chemotherapy infusions declined significantly to much lower levels (as measured at the 'nadir day' of the first chemotherapy cycle), although plasma levels remained somewhat higher than in patients without supplementation (Table 1) .
Haematological parameters
At the start of each subsequent chemotherapy cycle, a progressive decrease in blood haemoglobin concentrations was observed (Table 2) . White blood cell counts decreased after each cycle, returning to baseline levels at the beginning of the next cycle (results not shown). No significant differences were observed between patients who received antioxidant supplementation or placebo (Table 2) .
Liver function
Plasma levels of bilirubin, ALAT and, to a lesser extent, ASAT, GGT and lactate dehydrogenase increased significantly during each chemotherapy cycle, returning to baseline levels at the start of the next course (Table 2) . Importantly, the appearance of NPBI occurred shortly after administration of chemotherapy and reached its maximal level (peak value) days before the increase in plasma levels of bilirubin, ASAT and ALAT occurred. Plasma levels of alkaline phosphatase remained unchanged during chemotherapy (results not shown). Liver function parameters were not significantly different between patients receiving antioxidant supplementation or placebo, nor between patients treated with BEP, CD and the other cisplatin-based combination chemotherapy regimens.
Renal function
The mean renal function (glomerular filtration rate) did not change significantly during the course of chemotherapy (Table 2 ). Plasma magnesium concentrations gradually decreased during chemotherapy (results not shown). Subgroup analyses did not reveal any significant difference between the various subgroups with respect to renal function and plasma magnesium concentrations.
Hearing function
At follow-up, there was a significant increase in conduction thresholds at 8 kHz after three cycles (Table 2) . No significant differences were found between the various subgroups analysed.
Correlation analysis
During the first chemotherapy cycle, the peak concentration of NPBI correlated significantly both with the initial blood haemoglobin concentrations at the start of treatment, the decrease in blood haemoglobin concentrations and white blood cells, expressed as World Health Organization toxicity (r = 0.44, 0.40 and 0.50 respectively), and the peak ALAT ( Figure 2 ) and bilirubin ( Figure 3 ) concentrations (r = 0.421 and 0.489 respectively). Patients with the highest peak plasma NPBI concentration (cut-off > 10 µmol/l) during the first chemotherapy cycle had a significantly greater loss in their renal function (P = 0.003), whereas patients with the highest peak plasma NPBI concentration during the fourth chemotherapy cycle had the greatest degree of hearing loss of the high tones (8 kHz) after three chemotherapy cycles (NPBI cut-off point > 7 µmol/l; P = 0.035). No significant correlations were found between plasma antioxidant levels and plasma NPBI. Furthermore, antitumor response did not correlate with plasma NPBI.
DISCUSSION
The present study is the first in which NPBI is found in plasma of patients treated with chemotherapy for solid malignancies, indicating that iron plasma overload occurs in these patients. The appearance of NPBI occurred concomitantly with the increase in total plasma iron and decrease in LIBC, whereas detectable NPBI was only found in the plasma of those patients with a marked decrease of LIBC, indicating that the large iron-binding capacity of normal plasma had been saturated before increments in total iron led to circulation of potentially toxic NPBI. The changes in iron status were accompanied by a marked decrease in plasma antioxidant concentrations.
The observed significantly higher plasma peak levels of NPBI during the first chemotherapy cycle in germcell cancer patients as compared with the other patient treatment groups may be related to bleomycin in their BEP chemotherapy regimen, as bleomycin has been demonstrated to generate substantial amounts of free radicals [7] . In the patients who received antioxidant supplementation, the observed changes in plasma iron parameters did not differ from those in patients who did not receive supplementation.
Plasma NPBI correlated strongly with haematological toxicity, liver dysfunction and renal toxicity, suggesting that damage of bone marrow and/or red blood cells, the liver and the kidney contributed to, or caused, NPBI. Indeed, NPBI could arise from more than one source. For instance, NPBI could arise from liberation of iron from necrotic cells as a result of free-radical-mediated organ damage, low-grade intravascular haemolysis [26] or blockage of enzymic steps in porphyrin metabolism [27], leading to impaired bone marrow iron uptake and decreased iron incorporation into the erythroblastic precursors [28, 29] . The rise in NPBI does not seem to result from administration of red blood cell transfusions, as only two out of seven patients transfused within 8 days prior to the determination of NPBI had detectable NPBI in the plasma during the fourth chemotherapy cycle (0.6 and 16 µmol/l).
The increase in plasma liver enzymes, in particular bilirubin and ASAT (more then ALAT), was not observed before or concomitantly, but a number of days following the first appearance of plasma NPBI, indicating that plasma NPBI is a primary event leading to liver damage. Cisplatin induces the formation of haem oxygenase. Haem oxygenase catalyses the opening of the haem ring and its conversion to biliverdin, leading to the production of bilirubin. During this process iron is released from haem and carbon monoxide is generated. Iron may be chelated by ferritin, a molecule which formation is stimulated by haem oxygenase.
Chemotherapy-induced damage of the liver [30] , the major extrahaematopoietic depot of iron, perhaps in combination with a failure of hepatic iron sequestration, may in itself result in further release of iron. Correlations between NPBI and elevation of liver enzymes and liver graft versus host disease were also found in patients treated with high-dose chemotherapy for haematological malignancies [15, 16] , although levels of NPBI were, in general, much lower than those observed in our patient group [14] [15] [16] [17] [18] [19] [20] . Importantly, up to a third of patients mentioned in these studies already had detectable NPBI before the start of chemotherapy, indicating that other mechanisms apart from chemotherapy play a role in the pathogenesis of NPBI in those haematological patients. The lower levels of NPBI observed may, in some cases, be explained by the use of another NPBI detection method, the nitrilotriacetic acid assay, that may show false negative results due to chelation of transferrin-bound iron [18, 19] . Furthermore, in our patients, the bivalent platinum ion could, by competition, specifically displace iron from its binding sites on transport proteins, such as transferrin, leading to the rise in NPBI [31, 32] .
Cisplatin has been shown to induce haem oxygenase in the kidneys, resulting in increased renal haem [9, 10, 33] and kidney ferritin (a chelator for NPBI) [33] . Haem oxygenase catalyses the conversion of haem to biliverdin and ultimately to bilirubin [34] (Figure 4 ). During this process, iron is released from haem. Thus haem proteins, as part of various enzymes in the kidneys (and other organs), may be a major source of iron and NPBI.
Although patients receiving supplements did exhibit an initial significant rise in plasma vitamin C and E levels, these levels were not maintained and declined markedly in all patients during chemotherapy, suggesting consumption due to oxidative stress, renal loss of watersoluble antioxidants (e.g. vitamin C) or inadequate intake or absorption of the orally supplemented antioxidants during chemotherapy administration [12] . This may explain why supplementation of the limited number of antioxidants failed to protect against the release of NPBI.
The repetitive release of high concentrations of NPBI in each subsequent cycle in our patients may have resulted in an increased production of ferritin during the course of chemotherapy, indicating a prolonged plasma, and perhaps even body, iron overload state, which will enhance further the organ damage following chemotherapy.
The release of pro-oxidative NPBI seems to be an early primary event in chemotherapy-induced toxicity, which may lead to the generation of hydroxyl radicals, oxidative stress and secondary failure of antioxidant defences, resulting in the marked decline of antioxidants measured. The presence of NPBI may not only initiate, but also exacerbate, the toxicity of the chemotherapeutic regimens due to the oxidative damage inflicted by released NPBI. Because accumulation of NPBI will be deleterious to organ function and iron chelators have been shown to significantly protect against cisplatin-induced toxicities in animal studies [35] , investigation of these agents in patients undergoing cisplatin-based chemotherapy is recommended as a potential route to ameliorate the toxicity of chemotherapy.
